drugset / Trial / NCT06008119
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, Phase 3 study
Timeline
- Start
- 2023-10-25
- Primary completion
- 2026-12-24
- Completion
- 2026-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Cetuximab | Monoclonal antibody | — | — |
| Subject | Tunlametinib | Small molecule | 12 mg | — |
| Subject | Vemurafenib | Small molecule | 720 mg | — |